RT Journal Article
T1 Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
A1 Herrera-Martinez, Aura D
A1 Gahete, Manuel D
A1 Sanchez-Sanchez, Rafael
A1 Alors-Perez, Emilia
A1 Pedraza-Arevalo, Sergio
A1 Serrano-Blanch, Raquel
A1 Martinez-Fuentes, Antonio J
A1 Galvez-Moreno, Maria A
A1 Castaño, Justo P
A1 Luque, Raul M
K1 Neoplasm staging
K1 Neuroendocrine tumors
K1 Pancreatic neoplasms
K1 Predictive value of tests
K1 Receptors, ghrelin
K1 Stomach neoplasms
AB The association between the presence and alterations of the components of the ghrelin system and the development and progression of neuroendocrine tumors (NETs) is still controversial and remains unclear. Here, we systematically evaluated the expression levels (by quantitative-PCR) of key ghrelin system components of in gastroenteropancreatic (GEP)-NETs, as compared to non-tumor adjacent (NTA; n = 42) and normal tissues (NT; n = 14). Then, we analyzed their putative associations with clinical-histological characteristics. The results indicate that ghrelin and its receptor GHSR1a are present in a high proportion of normal tissues, while the enzyme ghrelin-O-acyltransferase (GOAT) and the splicing variants In1-ghrelin and GHSR1b were present in a lower proportion of normal tissues. In contrast, all ghrelin system components were present in a high proportion of tumor and NTA tissues. GOAT was significantly overexpressed (by quantitative-PCR (qPCR)) in tumor samples compared to NTA, while a trend was found for ghrelin, In1-ghrelin and GHSR1a. In addition, expression of these components displayed significant correlations with key clinical parameters. The marked overexpression of GOAT in tumor samples compared to NTA regions was confirmed by IHC, revealing that this enzyme is particularly overexpressed in gastrointestinal NETs, where it is directly correlated with tumor diameter. These results provide novel information on the presence and potential pathophysiological implications of the ghrelin system components in GEP-NETs, wherein GOAT might represent a novel diagnostic biomarker.
PB Wolters Kluwer Health
YR 2018
FD 2018-08-17
LK http://hdl.handle.net/10668/13047
UL http://hdl.handle.net/10668/13047
LA en
NO Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, et al. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. Clin Transl Gastroenterol. 2018 Oct 8;9(10):196
DS RISalud
RD Apr 4, 2025